Nath Bio-Genes (India) Limited
8,333words
161turns
11analyst exchanges
6executives
Management on call
Satish Kagliwal
MANAGING DIRECTOR –
Devinder Khurana
EXECUTIVE VICE
Amol Gupta
CHIEF FINANCIAL OFFICER –
Harish Pandey
SALES LEAD – NATH BIO-
Venkatesh Kulkarni
RESEARCH LEAD –
Deepika Sharma
GO INDIA ADVISORS LLP
Key numbers — 35 extracted
rs,
6%
1.11 million
26.3%
10%
7.3%
25%
3.7%
5.29%
15.9%
INR3,199 million
21.3%
Advertisement
Guidance — 20 items
Satish Kagliwal
opening
“Through our extensive product evaluation process, we have identified several promising hybrids across key crops that have shown superior performance and will be introduced commercially in coming seasons.”
Amol Gupta
opening
“The receivables will be recovered in the -- during the due course of the business and the inventory will obviously come down by the sales in FY '26.”
Devinder Khurana
qa
“Vegetable, some part of mustard and nutrient supplement will be the basic contributors in H2.”
Majid Ahamed
qa
“So what are the steps are you taking to improve the operational efficiency in the coming quarters -- in lean quarters like quarter 2 going forward?”
Majid Ahamed
qa
“So what type of seeds or different things that you're trying to bring in the market to ensure there is an evenness among other quarters going forward, like any kind of initiatives are you trying to do that?”
Majid Ahamed
qa
“So my question is that going forward to ensure that we have a steady growth, like even apart from Q1, what type of steps or what type of strategic initiatives the company is taking, sir?”
Satish Kagliwal
qa
“So we believe that every year, there will be a significant improvement in the product portfolio, product basket will improve, and that should result into much higher value.”
Satish Kagliwal
qa
“So it's the next 3 to 4 years' time, you will see a significant change the way we are going forward.”
Majid Ahamed
qa
“How do you expect the working capital levels to trend for the rest of FY '26, sir?”
Majid Ahamed
qa
“Sir, how do you expect working capital levels to trend for the rest of FY '26?”
Risks & concerns — 12 flagged
Bajra saw a moderate decline due to lower acreages and softer rural sentiment, though the overall portfolio impact remained limited.
— Satish Kagliwal
The bajra shows some decline trend, primarily due to the lower acreage and uneven monsoon in the key area for bajra.
— Amol Gupta
First is what caused the decline in bajra volumes?
— Prathna
So it was -- so it's not a major decline.
— Harish Pandey
It's hardly 5% or 6% decline in the bajra market.
— Harish Pandey
Bajra continues to be uncertain crop all around because it goes into areas where rainfall is not sure all around.
— Satish Kagliwal
See, the tariff is allowing the -- let's say, there is a pressure to allow GM corn, mainly GM corn or let's say, GM soya, seed, not our seeds, but the grain into the country.
— Satish Kagliwal
So since India has not permitted GM cultivation here, there has been resistance from our government not to permit that kind of a thing, but there is a pressure.
— Satish Kagliwal
We are ---see whatever decline in the traditional cotton sale or organized sector sales, I think we, along with other 2, 3 small companies, we have only grown.
— Harish Pandey
For abiotic stress, we have some spots wherein we conduct trials on no spray, no irrigation basis to understand how the products perform under these stress conditions, which is -- and we also have a very specialized program on heat tolerance because Nath Bio-Genes considers heat tolerance as a trait of global importance and we are working on that.
— Venkatesh Kulkarni
What happens in the share market is not our concern.
— Devinder Khurana
This is what my concern because I am an individual investor so...
— Rajesh
Advertisement
Q&A — 11 exchanges
Speaking time
54
15
13
10
10
9
8
7
6
6
Advertisement
Opening remarks
Deepika Sharma
Thank you, Amshadh. Good afternoon, everyone, and welcome to the Q2 and H1 FY '26 Earnings Call of Nath-Bio-Genes Limited. We have on the call Mr. Satish Kagliwal, Managing Director; Dr. Devinder Khurana, Executive Vice President; Mr. Amol Gupta, Chief Financial Officer; Mr. Harish Pandey, Sales Lead; Dr. Venkatesh Kulkarni, Research Lead. We must remind you that the discussion on today's call may include certain forward-looking statements and must be therefore viewed in conjunction with the risks that the company faces. May I now request the management to take us through the financials and the business outlook, subsequent to which we will open the floor for Q&A. Thank you, and over to you, sir.
Satish Kagliwal
Thank you, Deepika, and a very good afternoon to all the investors present. I extend you all a warm welcome to our Q2 and first half of financial year '26 Earnings Conference Call. I'm Satish Kagliwal, MD of the company. Friends, the first half of financial year '26 has been a period that truly tested the resilience of Indian agriculture and also reaffirmed the strength of Nath Bio-Genes. Despite uneven monsoons, erratic rainfall and evolving market dynamics, our teams on the ground have continued to deliver consistent results and strengthen farmer trust in our products. At a time when climate unpredictability is posing serious challenges to our farmers, seed industry's role becomes even more critical. When our farmers are struggling to protect their livelihoods against nature's vagaries, we see it as our responsibility, not just an opportunity to empower them, empower the farmers with seed and technology that can withstand these uncertainties and still deliver good yield. This sense o
Amol Gupta
Thank you, MD, sir, and good afternoon, everyone. Thank you for joining us today for H1 FY '26 earnings call. Our earnings presentation has been uploaded on the stock exchanges and the company website. And I hope you have had the chance to review it. Before we move into the detailed financials, let me briefly take you through the key operational highlights for H1 FY '26. As MD sir has informed you that cotton reported a steady growth of around 6% Y-o-Y in volume, reaching 1.11 million packets, while the growth in value is almost 26.3%, supported by healthy demand for our premium products like Sanket, RANA and strong channel presence and the efforts of the team on the field. We hope it will continue to remain our key revenue driver. Paddy delivered a steady growth, a nominal growth in volume, but the value growth is almost 10%, highlighting the success in the strategy of the company for promoting hybrid paddy. The bajra shows some decline trend, primarily due to the lower acreage and un
Advertisement